MX9307623A - PROTEIN PRODUCTION AND PROTEIN ADMINISTRATION. - Google Patents

PROTEIN PRODUCTION AND PROTEIN ADMINISTRATION.

Info

Publication number
MX9307623A
MX9307623A MX9307623A MX9307623A MX9307623A MX 9307623 A MX9307623 A MX 9307623A MX 9307623 A MX9307623 A MX 9307623A MX 9307623 A MX9307623 A MX 9307623A MX 9307623 A MX9307623 A MX 9307623A
Authority
MX
Mexico
Prior art keywords
dna sequences
cell
selectable marker
cells
endogenous gene
Prior art date
Application number
MX9307623A
Other languages
Spanish (es)
Inventor
Douglas A Treco
Michael L Heartlein
Richard F Selden
Original Assignee
Transkaryotic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transkaryotic Therapies filed Critical Transkaryotic Therapies
Publication of MX9307623A publication Critical patent/MX9307623A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Method of activating expression of and amplifying an endogenous gene in genomic DNA of a vertebrate cell which is not expressed in the cell as obtained or is not expressed at significant levels in the cell as obtained, comprising the steps of: (a) transfecting cells with DNA sequences comprising: 1) exogenous DNA sequences which repair, alter, delete or replace a sequence present in the cell or which are regulatory sequences not normally functionally linked to the endogenous gene in the cell as obtained; 2) DNA sequences homologous with genomic DNA sequences at a preselected site in the cells; and 3) amplifiable DNA encoding a selectable marker; (b) maintaining the cells under conditions appropriate for homologous recombination to occur between DNA sequences homologous with genomic DNA sequences and genomic DNA sequences; (c) culturing the homologously recombinant cells produced in (b) under conditions which select from amplification of the amplifiable DNA encoding a selectable marker, whereby the amplifiable DNA encoding a selectable marker and the endogenous gene functionally linked to exogenous DNA of (a) 1) are coamplified.
MX9307623A 1992-12-03 1993-12-02 PROTEIN PRODUCTION AND PROTEIN ADMINISTRATION. MX9307623A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98558692A 1992-12-03 1992-12-03

Publications (1)

Publication Number Publication Date
MX9307623A true MX9307623A (en) 1994-06-30

Family

ID=25531613

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9307623A MX9307623A (en) 1992-12-03 1993-12-02 PROTEIN PRODUCTION AND PROTEIN ADMINISTRATION.

Country Status (15)

Country Link
EP (1) EP0672160B8 (en)
JP (2) JPH08503856A (en)
KR (1) KR100364916B1 (en)
AT (1) ATE477327T1 (en)
AU (1) AU689455B2 (en)
CA (1) CA2151032A1 (en)
DE (1) DE69334340D1 (en)
DK (1) DK0672160T3 (en)
IL (1) IL107822A (en)
MX (1) MX9307623A (en)
MY (1) MY140230A (en)
NZ (3) NZ259165A (en)
SG (1) SG46476A1 (en)
TW (1) TW402639B (en)
WO (1) WO1994012650A2 (en)

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5968502A (en) * 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
DK0731845T3 (en) * 1993-12-23 2003-10-20 Merck & Co Inc Homologous recombinant antibody expression system for murine cells
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6130071A (en) * 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6737513B1 (en) 1996-06-07 2004-05-18 Icos Corporation Macrophage derived chemokine (MDC) and chemokine analogs and assay to identify modulators of MDC activity, and therapeutic uses for same
US7018627B1 (en) 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US5965125A (en) 1995-10-25 1999-10-12 Transkaryotic Therapies, Inc. Hybrid matrix implants and explants
US6419920B1 (en) 1995-10-25 2002-07-16 Trans Karyotic Therapies, Inc. Hybrid matrix implants and explants
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US5989914A (en) * 1996-06-03 1999-11-23 Universite Laval Integration cassette for improvement of transgenesis in eukaryotes
SG94355A1 (en) 1996-10-01 2003-02-18 Geron Corp Human telomerase catalytic subunit
ES2312179T3 (en) 1996-12-06 2009-02-16 Amgen Inc. COMBINED THERAPY USING AN IL-1 INHIBITOR FOR THE TREATMENT OF ILL-1 ILLNESSES.
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
KR20010020375A (en) * 1997-04-30 2001-03-15 무레 미카엘 에프. In vivo use of recombinagenic oligonucleobases to correct genetic lesions in hepatocytes
US5888809A (en) * 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US6172211B1 (en) 1997-07-11 2001-01-09 Boehringer Ingelheim International Gmbh Nucleic acid encoding tag7 polypeptide
TR200000140T2 (en) 1997-07-23 2000-05-22 Roche Diagnostics Gmbh Determination of human cell lines for human protein production by endogenic gene activity
PT1000154E (en) 1997-07-23 2007-03-30 Roche Diagnostics Gmbh Identification of human cell lines for the production of human proteins by endogenous gene activation
US6391633B1 (en) 1997-07-23 2002-05-21 Roche Diagnostics Gmbh Production of erythropoietin by endogenous gene activation
US6548296B1 (en) 1997-07-23 2003-04-15 Roche Diagnostics Gmbh Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
JP2001511341A (en) * 1997-07-23 2001-08-14 ロシュ ダイアグノスティックス ゲーエムベーハー Production of human mutant proteins by homologous recombination in human cells
TR200000175T2 (en) * 1997-07-23 2001-01-22 Roche Diagnostics Gmbh Preparation of erythropoietin with endogenic gene activation.
AU776280B2 (en) * 1997-07-23 2004-09-02 Roche Diagnostics Gmbh Production of erythropoietin by endogenous gene activation
US7316923B1 (en) 1997-09-26 2008-01-08 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
US6897066B1 (en) 1997-09-26 2005-05-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
US5932465A (en) * 1997-10-16 1999-08-03 Icos Corporation Phosphodiesterase 8A
JP4441112B2 (en) 1997-11-03 2010-03-31 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド VEGI is an inhibitor of angiogenesis and tumor growth
AU757930B2 (en) * 1997-12-01 2003-03-13 Roche Diagnostics Gmbh Optimization of cells for endogenous gene activation
CN1280309C (en) 1997-12-03 2006-10-18 罗切诊断学有限公司 Erythropoietin with high specific activity
CA2321224A1 (en) 1998-02-23 1999-08-26 Icos Corporation Phosphodiesterase 10
AU3066699A (en) 1998-03-03 1999-09-20 Johns Hopkins University, The Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
US6479256B1 (en) 1998-03-04 2002-11-12 Icos Corporation Lectomedin materials and methods
US6200951B1 (en) 1998-03-12 2001-03-13 Icos Corporation Chitinase chitin-binding fragments
EP1982990A1 (en) 1998-03-19 2008-10-22 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6541623B1 (en) 1998-04-03 2003-04-01 Hyseq, Inc. Interleukin—1 receptor antagonist and uses thereof
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6426191B1 (en) 1998-04-03 2002-07-30 Hyseq, Inc. Assays involving an IL-1 receptor antagonist
US6294655B1 (en) 1998-04-03 2001-09-25 Hyseq, Inc. Anti-interleukin-1 receptor antagonist antibodies and uses thereof
US6071691A (en) * 1998-04-27 2000-06-06 Oregon Health Science University Materials and methods for modulating differentiation
US6492138B1 (en) 1998-05-21 2002-12-10 Amgen Canada Inc. Polynucleotides encoding a novel SHC-binding protein
US6447771B1 (en) 1999-03-19 2002-09-10 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
US6387645B1 (en) 1998-07-16 2002-05-14 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
US6476211B1 (en) 1998-07-16 2002-11-05 Hyseq, Inc. Methods and materials relating to CD39-like polypeptides
MXPA01000481A (en) 1998-07-16 2002-11-29 Hyseq Inc Methods and materials relating to novel cd39-like polypeptides.
DE19857609A1 (en) 1998-12-14 2000-06-15 Hannelore Ehrenreich Use of erythropoietin for the treatment of human cerebral ischemia
DK1139793T3 (en) 1998-12-23 2010-03-01 Sinai School Medicine Bitter taste response inhibitors
US6780977B1 (en) 1999-01-29 2004-08-24 Nuvelo, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
US6899875B1 (en) 1999-01-29 2005-05-31 Nuvelo, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
US6350447B1 (en) 1999-01-29 2002-02-26 Hyseq, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
WO2000049162A2 (en) * 1999-02-19 2000-08-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
CA2363779A1 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6335013B1 (en) 1999-03-19 2002-01-01 Hyseq, Inc. Methods and materials relating to CD39-like polypeptides
WO2000077179A2 (en) 1999-06-16 2000-12-21 Icos Corporation Human poly(adp-ribose) polymerase 2 materials and methods
US6632665B1 (en) 1999-08-09 2003-10-14 Wake Forest University Human gene encoding 3′-5′ exonuclease
EP2030986A1 (en) 1999-09-29 2009-03-04 The General Hospital Corporation Polypeptide derivative of parathyroid hormone (PTH)
US6344549B1 (en) 1999-10-14 2002-02-05 Icos Corporation ATR-2 cell cycle checkpoint
EP1222273A2 (en) 1999-10-22 2002-07-17 PHARMACIA & UPJOHN COMPANY Drosophila g protein coupled receptors, nucleic acids, and methods related to the same
US7314716B2 (en) 1999-11-19 2008-01-01 Mount Sinai School Of Medicine Gustducin γ subunit materials and methods
AU1647501A (en) 1999-12-10 2001-06-18 Cytos Biotechnology Ag Replicon based activation of endogenous genes
US6635742B1 (en) 2000-01-25 2003-10-21 Nuvelo, Inc. Antibodies specific for semaphorin-like polypeptides
US6465620B1 (en) 2000-01-21 2002-10-15 Hyseq, Inc. Methods and materials relating to novel von Willebrand/Thrombospondin-like polypeptides and polynucleotides
US6586390B1 (en) 2000-01-21 2003-07-01 Hyseq, Inc. Methods and materials relating to novel prothrombinase-like polypeptides and polynucleotides
EP1728862A1 (en) 2000-03-16 2006-12-06 Genetica, Inc. Methods and compositions for RNA interference
US20030084471A1 (en) 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
CA2747325A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001274894A1 (en) 2000-05-22 2001-12-03 Pharmacia And Upjohn Company Novel matrix metalloproteinases
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
AU2001271839A1 (en) 2000-07-05 2002-01-14 Pharmacia And Upjohn Company Human ion channels
GB0018876D0 (en) 2000-08-01 2000-09-20 Applied Research Systems Method of producing polypeptides
ATE497007T1 (en) 2000-08-25 2011-02-15 Basf Plant Science Gmbh POLYNUCLEOTIDES CODING FOR PRENYL PROTEASES FROM PLANT
US6787684B2 (en) 2000-10-16 2004-09-07 E. & J. Gallo Winery Lipoxygenase genes from Vitis vinifera
ATE505204T1 (en) 2000-12-20 2011-04-15 Hoffmann La Roche CONJUGATES OF ERYTHROPOIETIN (EPO) WITH POLYETHYLENE GLYCOL (PEG)
KR100896971B1 (en) 2001-02-02 2009-05-14 오르토-맥네일 파마슈티칼, 인코퍼레이티드 Treatment of neurological dysfunction, including fructopyranose sulfamate and erythropoietin
EP1366058B1 (en) 2001-02-09 2011-01-26 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7803982B2 (en) 2001-04-20 2010-09-28 The Mount Sinai School Of Medicine Of New York University T1R3 transgenic animals, cells and related methods
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
NZ532988A (en) 2001-11-28 2008-04-30 Ortho Mcneil Pharm Inc Erythropoietin dosing regimen for treating anemia
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
GB0200977D0 (en) * 2002-01-17 2002-03-06 Lonza Biologics Plc Glutamine-auxotrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium
AU2003226960B2 (en) 2002-01-17 2007-11-22 Lonza Biologics Plc. Glutamine-auxothrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium
KR20110014661A (en) 2002-02-07 2011-02-11 노보자임스 바이오파마 디케이 에이/에스 Albumin-Fusion Kunitz Domain Peptides
AU2003218045A1 (en) 2002-03-11 2003-09-29 Ortho Mcneil Pharmaceutical, Inc Methods for shp1 mediated neuroprotection
EP1531848A4 (en) 2002-06-10 2007-03-28 Vaccinex Inc GENE EXPRESSING DIFFERENTIAL FA IN BREAST AND BLADDER CANCER AND CODED POLYPEPTIDES
AU2003254016A1 (en) 2002-07-19 2004-02-09 Catholic Healthcare West Methods and compositions relating to chimeric nicotinic receptor subunits
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
CA2513251C (en) 2003-01-14 2013-03-19 Dana-Farber Cancer Institute Cancer therapy sensitizer
WO2004071462A2 (en) 2003-02-12 2004-08-26 Johns Hopkins University Methods and compositions for treatment of viral infections based on tsg101-vps28 interaction
EP1639005B1 (en) 2003-06-27 2017-05-03 Monell Chemical Senses Center Taste receptors of the t1r family from domestic cat
AU2005247858A1 (en) 2004-04-14 2005-12-08 Monell Chemical Senses Center Taste receptors of the T1R family from domestic dog
AU2005240002B2 (en) 2004-04-23 2009-06-18 Zoetis Services Llc Cellular permissivity factor for viruses, and uses thereof
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
DK1797183T3 (en) 2004-09-02 2012-10-01 Univ Yale REGULATION OF ONCOGENES WITH MICRORNAS
US7785807B2 (en) 2004-12-13 2010-08-31 Monell Chemical Senses Center Voltage-gated, pH-sensitive anion channel and its novel splice variant involved in taste sensation
WO2007002528A1 (en) 2005-06-23 2007-01-04 Yale University Anti-aging micrornas
WO2007142667A2 (en) 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Treatment of patients with autoantibody positive disease
CA2626852A1 (en) 2005-11-03 2007-05-18 Redpoint Bio Corporation High throughput screening assay for the trpm5 ion channel
DE102006004008A1 (en) 2006-01-27 2007-08-02 Hannelore Prof. Dr. Dr. Ehrenreich Treating or preventing multiple sclerosis comprises administering erythropoietin for periods separated by intervals in which no erythropoietin is administered
CN101062407A (en) 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 Function of erythropoietin in the preventing and treating of retinal injury
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2008013861A2 (en) 2006-07-27 2008-01-31 Redpoint Bio Corporation Screening assay for inhibitors of trpa1 activation by a lower alkyl phenol
WO2008019368A2 (en) 2006-08-07 2008-02-14 Teva Biopharmaceuticals Usa, Inc. Albumin-insulin fusion proteins
EP1900749A1 (en) 2006-09-12 2008-03-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nucleic acids for expressing a polynucleotide of interest in mammalian cancer cells
WO2008114673A1 (en) 2007-03-15 2008-09-25 Chugai Seiyaku Kabushiki Kaisha Method for production of polypeptide
KR101461659B1 (en) 2007-05-11 2014-11-17 토마스 제퍼슨 유니버시티 Methods of treatment and prevention of neurodegenerative diseases and disorders
AU2008251467B2 (en) 2007-05-11 2014-07-31 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
US9931377B2 (en) 2007-06-27 2018-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cell expressing complexes of IL-15 and IL-15Ralpha
AR067536A1 (en) 2007-07-17 2009-10-14 Hoffmann La Roche METHOD FOR OBTAINING A MONO-PEGILATED ERYTHROPOYETIN IN A SUBSTANTIALLY HOMOGENOUS FORM
CL2008002053A1 (en) 2007-07-17 2009-05-22 Hoffmann La Roche Method for the purification of a monopeglated erythropoietin (epompeg) which consists of providing a solution containing mono, poly and non-peglated erythropoietin and passing it through two steps of cation exchange chromatography and a method to produce epo mpeg that includes a purification method.
WO2009010107A1 (en) 2007-07-19 2009-01-22 Hannelore Ehrenreich Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
ES2567561T3 (en) 2007-07-27 2016-04-25 Universiteit Gent Permissive cells and their uses
JP5711966B2 (en) 2007-08-01 2015-05-07 ザ ジェネラル ホスピタル コーポレイション Screening methods using G protein-coupled receptors and related compositions
DK2186905T3 (en) 2007-08-07 2016-09-19 Chugai Pharmaceutical Co Ltd Method of Preparation of Heterogeneous Protein
US9802993B2 (en) 2007-10-15 2017-10-31 Chugai Seiyaku Kabushiki Kaisha Method for producing a cell for protein production by treating a cell overexpressing a taurine transporter with methotrexate
DK2213746T3 (en) 2007-10-24 2015-08-03 Chugai Pharmaceutical Co Ltd CELL FOR USE IN THE PREPARATION OF exogenous protein, AND MANUFACTURING METHOD THAT USE CELL
NZ586947A (en) 2008-02-08 2012-11-30 Ambrx Inc Modified leptin polypeptides and their uses
GB0803076D0 (en) 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
CN107022020A (en) 2008-09-26 2017-08-08 Ambrx公司 The animal erythropoietin polypeptides and its purposes of modification
US8110185B2 (en) 2008-10-03 2012-02-07 St. Michael's Hospital Method for preventing and treating cardiovascular diseases with BRCA1
NZ603996A (en) 2009-02-02 2014-03-28 Chromocell Corp Cells or cell lines that stably express a bitter taste receptor and methods of making them
WO2010123014A1 (en) 2009-04-22 2010-10-28 中外製薬株式会社 Method for preparing cell highly producing heterogeneous protein
EP2460006A2 (en) 2009-07-31 2012-06-06 Chromocell Corporation Methods and compositions for identifying and validating modulators of cell fate
CA2769651A1 (en) 2009-08-05 2011-02-10 Chromocell Corporation Improved plants, microbes, and organisms
EP2464661B1 (en) 2009-08-13 2018-01-17 The Johns Hopkins University Methods of modulating immune function with anti-b7-h7cr antibodies
WO2011090971A2 (en) 2010-01-19 2011-07-28 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for male reproductive disorders
BR112012028949B1 (en) 2010-05-13 2020-11-17 Chugai Seiyaku Kabushiki Kaisha parathyroid hormone analog polypeptide, its use and production method, as well as nucleic acid, expression vector, cell and pharmaceutical composition
JP5735650B2 (en) 2010-09-14 2015-06-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Method for purifying PEGylated erythropoietin
US20130224797A1 (en) 2010-10-15 2013-08-29 Jcr Pharmaceuticals Co., Ltd. Method for producing glycoprotein having mannose residue as non-reducing end of sugar chain
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
JP6219170B2 (en) 2011-02-07 2017-10-25 セレニス セラピューティクス ホールディング エスアー Lipoprotein complex and its production and use
CA2828811C (en) 2011-03-03 2021-09-21 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
TWI674272B (en) 2011-04-01 2019-10-11 中外製藥股份有限公司 Nucleic acid molecule with APES activity
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
WO2013009971A1 (en) 2011-07-12 2013-01-17 E. I. Du Pont De Nemours And Company Detection and screening method and materials useful in performance thereof
WO2013020044A1 (en) 2011-08-03 2013-02-07 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Treatment of fibrosis using microrna-19b
WO2014012082A2 (en) 2012-07-13 2014-01-16 Zymeworks Inc. Multivalent heteromultimer scaffold design an constructs
WO2014016873A1 (en) 2012-07-26 2014-01-30 Jcr Pharmaceuticals Co., Ltd. Method for production of recombinant human alpha-galactosidase a
US11608508B2 (en) 2012-10-10 2023-03-21 Chugai Seiyaku Kabushiki Kaisha Method for establishing modified host cell
JP6359019B2 (en) 2012-10-24 2018-07-18 ノバルティス アーゲー IL-15Rα type, cells expressing IL-15Rα type, and therapeutic use of IL-15Rα and IL-15 / IL-15Rα complex
EP2970420A4 (en) 2013-03-15 2016-08-17 Apotex Inc Enhanced liquid formulation stability of erythropoietin alpha through purification processing
WO2014152497A2 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for cognitive disorders
CA2910945A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
WO2016018920A1 (en) 2014-07-29 2016-02-04 Admune Therapeutics Llc Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
KR102617137B1 (en) 2014-09-15 2023-12-27 칠드런'즈 메디컬 센터 코포레이션 Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation
US10413597B2 (en) 2014-09-29 2019-09-17 Alexion Pharmaceuticals, Inc. Methods of treating Mucopolysaccharidosis IIIB (MPSIIIB)
US11191811B2 (en) 2014-11-19 2021-12-07 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for frailty associated with aging
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2016116966A1 (en) 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
SG11201811553UA (en) 2016-07-15 2019-01-30 Hoffmann La Roche Method for purifying pegylated erythropoietin
EP3570870A1 (en) 2017-01-20 2019-11-27 Novartis AG Combination therapy for the treatment of cancer
CA3046120A1 (en) 2017-01-20 2018-07-26 Novartis Ag Combination therapy for the treatment of cancer
CN111727063A (en) 2017-12-29 2020-09-29 豪夫迈·罗氏有限公司 Methods for providing pegylated protein compositions
ES2905105T3 (en) 2017-12-29 2022-04-07 Hoffmann La Roche Procedure for Providing a PEGylated Protein Composition
WO2019129876A1 (en) 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Process for providing pegylated protein composition
EP3830261A1 (en) * 2018-08-02 2021-06-09 Novozymes A/S Preparation of combinatorial libraries of dna constructs using introns
KR20220137651A (en) 2020-02-05 2022-10-12 노파르티스 아게 CHO cells expressing IL-15 heterodimer
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
IL317448A (en) 2022-06-10 2025-02-01 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
AU2023284357A1 (en) 2022-06-10 2025-01-23 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2024091824A1 (en) 2022-10-26 2024-05-02 Ada Forsyth Institute, Inc. Differentiation and reprogramming of chondrocyte
WO2024129459A1 (en) 2022-12-16 2024-06-20 University Of Rochester Repairmen! of barrier dysfunction in esophagus

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE56716B1 (en) * 1983-01-19 1991-11-20 Genentech Inc Method for producing human tpa and expression vectors therefor
US4822736A (en) * 1984-07-05 1989-04-18 Baylor College Of Medicine Amplification of adenosine deaminase genes in mammalian cells using adenosine, alanosine, uridine, and deoxycoformycin
US5043270A (en) * 1989-03-31 1991-08-27 The Board Of Trustees Of The Leland Stanford Junior University Intronic overexpression vectors
DE69018633T2 (en) * 1989-06-23 1995-08-10 The United States Of America Represented By The Secretary U.S. Department Of Commerce, Washington, D.C. EFFICIENT METHOD FOR DETECTABLE EXPRESSION OF NON-SELECTABLE GENES.
ATE156189T1 (en) * 1989-12-22 1997-08-15 Applied Research Systems MODIFICATION OF ENDOGENE GENE EXPRESSION USING A REGULATORY ELEMENT USING HOMOLOGOUS RECOMBINATION
BR9107210A (en) * 1990-12-07 1994-02-08 Univ Florida RECOMBINANT HOST CELL, CELL CELL, AND PROCESS TO PRODUCE CELL CELL
AU664847B2 (en) * 1991-05-15 1995-12-07 Cell Genesys, Inc. Genomic modifications with homologous DNA targeting
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production

Also Published As

Publication number Publication date
CA2151032A1 (en) 1994-06-09
NZ336200A (en) 2000-12-22
NZ329348A (en) 1999-10-28
JPH08503856A (en) 1996-04-30
DK0672160T3 (en) 2010-11-29
EP0672160A1 (en) 1995-09-20
AU5736294A (en) 1994-06-22
JP2005027673A (en) 2005-02-03
AU689455B2 (en) 1998-04-02
NZ259165A (en) 1998-01-26
EP0672160B1 (en) 2010-08-11
WO1994012650A2 (en) 1994-06-09
MY140230A (en) 2009-12-31
WO1994012650A3 (en) 1994-08-04
IL107822A (en) 2007-05-15
KR100364916B1 (en) 2003-03-31
EP0672160B8 (en) 2010-09-22
ATE477327T1 (en) 2010-08-15
IL107822A0 (en) 1994-04-12
KR950704502A (en) 1995-11-20
TW402639B (en) 2000-08-21
DE69334340D1 (en) 2010-09-23
SG46476A1 (en) 1998-02-20

Similar Documents

Publication Publication Date Title
MX9307623A (en) PROTEIN PRODUCTION AND PROTEIN ADMINISTRATION.
DE69027526D1 (en) PRODUCTION OF PROTEINS BY HOMOLOGOUS RECOMBINATION
ATE213020T1 (en) CLONING AND EXPRESSION OF BIOLOGICALLY ACTIVE ALPHA-GALACTOSIDASE A
CA2203569A1 (en) Nucleotide sequence encoding the enzyme i-scei and the uses thereof
JPS57141287A (en) Rennin, preprorennin or prorennin gene obtained from recombined dna material and live cell containing gene
ATE414782T1 (en) METHOD FOR PRODUCING POLYPEPTIDES IN MUTATED ASPERGILLUS CELLS
DE69333112D1 (en) MODIFIED FUNGUS CELLS AND METHOD FOR THE PRODUCTION OF RECOMBINANT PRODUCTS
ATE246251T1 (en) METHOD FOR PRODUCING POLYPEPTIDES IN SURFACTIN MUTANTS OF BACILLUS CELLS
ATE395424T1 (en) METHOD FOR PRODUCING HETEROLOGUE POLYPEPTIDES IN TRICHOTHECENE DEFICIENCY MUTANT FILAMENTOLOUS FUNGI
DE69635955D1 (en) IMPROVED INSTALLATION OF EXOGENERIC DNA IN PLANT CELLS
CA2037677A1 (en) Process for production of exogenous gene or its product in plant cells
EP2281892A3 (en) Methods for producing polypeptides in respiratory-deficient Trichoderma cells
FI924909A0 (en) BIO-SYNTHETIC FOUNDATION FOR CHEMICAL FRAMEWORK
AU2209988A (en) Method for increasing the expression of polypeptides in recombinant cell culture
ATE122097T1 (en) EXPRESSION VECTOR AND METHOD FOR THE REGULAtable PRODUCTION OF PROTEINS IN EUKARYONTES.
DE69736520D1 (en) MODIFYING CRYPTIC SPLICEMOTIVE HETEROLOGIC GENES FOR EXPRESSION IN MUSHROOMS
CA2297660A1 (en) Production of human mutated proteins in human cells by means of homologous recombination
NZ516885A (en) Introducing into a cell a nucleic acid fragment targetted to an amplifiable region of a chromosome whereby the fragment integrates into the chromosome and further identifying such cells
TW375656B (en) High-proliferative mutants of saccharomyces cerevisiae and induction method thereof, expression host derived therefrom and its use in over-expression of foreign proteins
DE69527994D1 (en) USE OF ANTISENSE SEQUENCES TO INCREASE THE RESPONSE TO GENE AMPLIFICATION